Buprenorphine

Major

Buprenorphine Mobocertinib Exkivity Explained An increased risk of QT interval prolongation Details Buprenorphine Modafinil Provigil Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Molindone Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Moricizine Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Morphine Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Morphine Sulfate Liposome Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Moxifloxacin Avelox An increased risk of QT interval prolongation Details Buprenorphine Nafarelin Explained An increased risk of QT interval prolongation Details Buprenorphine Nafcillin Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Nalbuphine Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Naratriptan Explained An increased risk of serotonin syndrome Details Buprenorphine Nefazodone Explained An increased risk of serotonin syndrome, increased buprenorphine exposure and an increased risk of buprenorphine-related adverse e... Details Buprenorphine Nelfinavir Viracept Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Netupitant Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Nevirapine Viramune Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Nicomorphine Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Nilotinib Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Nitrazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Nitrous Oxide Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Nordazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Norfloxacin Explained An increased risk of QT interval prolongation Details Buprenorphine Nortriptyline Explained An increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Octreotide Bynfezia An increased risk of QT interval prolongation Details Buprenorphine Ofloxacin Floxin® An increased risk of QT interval prolongation Details Buprenorphine Olanzapine Explained An increased risk of QT interval prolongation, an increased risk of CNS and respiratory depression and an increased risk of paraly... Details Buprenorphine Oliceridine Olinvyk Explained Reduced analgesic effect of oliceridine and an increased risk of serotonin syndrome Details Buprenorphine Olodaterol Striverdi Explained An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Buprenorphine Omaveloxolone Skyclarys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Buprenorphine Ondansetron Explained An increased risk of serotonin syndrome and QT interval prolongation Details Buprenorphine Opipramol Explained An increased risk of serotonin syndrome Details Buprenorphine Opium Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Opium Alkaloids Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Orphenadrine Explained Enhanced neuromuscular blocking action, an increased risk of respiratory depression and CNS depression and an increased risk of pa... Details Buprenorphine Osilodrostat Isturisa Explained Increased risk of QT interval prolongation Details Buprenorphine Osimertinib Tagrisso Explained Increased risk of QT interval prolongation Details Buprenorphine Oxaliplatin Explained Increased risk of QT-interval prolongation Details Buprenorphine Oxazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Oxcarbazepine Oxtellar Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Oxitropium Bromide Explained An increased risk of paralytic ileus Details Buprenorphine Oxybutynin Ditropan Explained An increased risk of paralytic ileus Details